Role of immunotherapy in the treatment of advanced non-small-cell lung cancer

Erika Rijavec, Carlo Genova, Angela Alama, Giulia Barletta, Claudio Sini, Paolo Pronzato, Simona Coco, Maria Giovanna Dal Bello, Graziana Savarino, Anna Truini, Francesco Boccardo, Francesco Grossi

Research output: Contribution to journalArticle


After several decades of modest results with nonspecific immune stimulants, immunotherapy has become an exciting approach in the treatment of cancer. Although non-small-cell lung cancer has not been considered an immunogenic disease for very long, a better understanding of tumor immunology and the identification of new targets have led to the development of many clinical trials of immune-based therapies for this neoplasm. Promising results from many clinical trials suggest that immunotherapy could be an effective strategy in the management of advanced non-small-cell lung cancer. Further studies are required to help clinicians in the selection of patients who are more likely to benefit from immunotherapy strategies by the identification of biomarkers and to understand when the combination of immunotherapy with other agents should be recommended.

Original languageEnglish
Pages (from-to)79-90
Number of pages12
JournalFuture Oncology
Issue number1
Publication statusPublished - Jan 1 2014


  • advanced non-small-cell lung cancer
  • cancer vaccine
  • CTLA-4
  • IL-2
  • immunotherapy
  • PD-1
  • TLF
  • TLR9

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Fingerprint Dive into the research topics of 'Role of immunotherapy in the treatment of advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Rijavec, E., Genova, C., Alama, A., Barletta, G., Sini, C., Pronzato, P., Coco, S., Bello, M. G. D., Savarino, G., Truini, A., Boccardo, F., & Grossi, F. (2014). Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. Future Oncology, 10(1), 79-90.